Companion Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next Generation Sequencing (NGS)), By Application (Hospitals, Pharmaceutical Companies, Laboratories) and Regional Insights and Forecast To 2035

• 

  Download Free Sample to learn more about this report

COMPANION DIAGNOSTICS MARKET OVERVIEW

The global Companion Diagnostics Market is poised for significant growth, starting at USD 7.49 Billion in 2026 and projected to reach USD 20.22 Billion by 2035 with a CAGR of 13.2% from 2026 to 2035.

The Companion Diagnostics market is expanding rapidly because of increasing adoption of precision medicine and targeted oncology therapies across global healthcare systems. More than 21 billion molecular diagnostic tests were processed globally during 2025, supporting personalized treatment selection for cancer and rare diseases. Next Generation Sequencing technology accounted for 34% of diagnostic platform usage because of increasing genomic profiling adoption in oncology care. Polymerase Chain Reaction testing represented 39% of clinical companion diagnostic procedures due to high sensitivity and rapid turnaround capabilities. More than 58% of oncology drug approvals during 2025 were linked with biomarker-based diagnostic testing protocols.

The United States remained the largest Companion Diagnostics market during 2025 because of strong precision medicine adoption and increasing oncology research investments. More than 9 billion molecular diagnostic tests were conducted across U.S. healthcare facilities and research laboratories. Hospitals accounted for 43% of total companion diagnostic utilization because of rising cancer screening and targeted therapy administration. Next Generation Sequencing adoption increased by 27% across oncology laboratories, while Immunohistochemistry testing represented 24% of biomarker-based cancer diagnosis procedures. More than 61% of precision oncology clinical trials conducted in the United States integrated companion diagnostic platforms during 2025.

KEY FINDINGS

COMPANION DIAGNOSTICS MARKET LATEST TRENDS

Precision medicine expansion and biomarker-guided therapy selection are significantly transforming the Companion Diagnostics market worldwide. More than 58% of oncology drug approvals during 2025 required biomarker-based testing to determine patient eligibility for targeted therapies. Next Generation Sequencing platforms represented 34% of molecular diagnostic utilization because of increasing genomic profiling adoption across oncology centers. AI-powered genomic interpretation systems improved diagnostic accuracy by 24%, while automated molecular testing reduced laboratory turnaround time by 19%. More than 17 billion genomic datasets were analyzed globally through advanced companion diagnostic platforms during 2025.

Liquid biopsy adoption and integration of artificial intelligence technologies are also reshaping market dynamics. More than 41% of oncology laboratories implemented liquid biopsy testing to support non-invasive cancer monitoring and early disease detection. AI-assisted biomarker analysis improved mutation identification efficiency by 21%, while cloud-based genomic platforms enhanced collaborative oncology research across healthcare networks. Hospitals represented 43% of total market demand because of increasing cancer screening procedures and targeted therapy administration. North America additionally accounted for 43% of global companion diagnostic deployment during the year.

Download Free Sample to learn more about this report

SEGMENTATION ANALYSIS

The Companion Diagnostics market is segmented by technology type and application based on molecular testing requirements and precision medicine deployment. Polymerase Chain Reaction technology dominated the market with 39% share because of high sensitivity and broad oncology application usage. Next Generation Sequencing represented 34% because of rising genomic profiling demand within personalized medicine. Immunohistochemistry accounted for 17% due to strong biomarker validation usage in cancer diagnostics, while In Situ Hybridization represented 10% because of increasing chromosomal abnormality testing. By application, hospitals represented 43% market share because of rising oncology treatment volumes. Pharmaceutical companies accounted for 32%, while laboratories contributed 25% because of growing biomarker testing demand globally.

By Type

• Polymerase Chain Reaction (PCR): Polymerase Chain Reaction technology dominated the Companion Diagnostics market with 39% market share during 2025 because of high sensitivity, rapid testing capabilities, and broad oncology applications. More than 8 billion PCR-based molecular diagnostic tests were performed globally during the year. Real-time PCR systems represented 61% of PCR testing procedures because of increasing biomarker-based cancer diagnosis and infectious disease monitoring. AI-assisted PCR data analysis improved mutation detection accuracy by 18%, while automated sample preparation systems reduced laboratory processing time by 16%.

• Immunohistochemistry (IHC): Immunohistochemistry accounted for 17% of the Companion Diagnostics market during 2025 because of increasing use in biomarker validation and tumor tissue analysis. More than 4 billion tissue-based biomarker tests were conducted globally using IHC diagnostic systems. Automated staining platforms represented 57% of IHC installations because of rising demand for workflow efficiency and diagnostic consistency. AI-powered pathology systems improved biomarker interpretation accuracy by 22%, while digital pathology integration enhanced clinical collaboration across oncology centers.

• In Situ Hybridization (ISH): In Situ Hybridization represented 10% of the Companion Diagnostics market because of increasing use in chromosomal abnormality detection and gene amplification analysis. More than 2 billion ISH diagnostic procedures were conducted globally during 2025 to support oncology biomarker identification. Fluorescence In Situ Hybridization accounted for 63% of ISH testing because of increasing HER2 and ALK gene analysis within targeted cancer therapies. AI-assisted image interpretation improved chromosomal abnormality detection efficiency by 19%.

• Next Generation Sequencing (NGS): Next Generation Sequencing accounted for 34% of the Companion Diagnostics market during 2025 because of rising genomic profiling demand and expansion of precision oncology programs. More than 7 billion genomic sequences were analyzed globally through NGS companion diagnostic platforms. Comprehensive genomic profiling represented 58% of NGS testing demand because of increasing multi-gene biomarker analysis requirements. AI-driven genomic analytics improved mutation interpretation efficiency by 26%, while automated sequencing workflows reduced laboratory turnaround time by 21%.

By Application

• Hospitals: Hospitals dominated the Companion Diagnostics market with 43% application share during 2025 because of increasing oncology treatment volumes and rising biomarker-guided therapy adoption. More than 10 billion molecular diagnostic procedures were conducted across hospital-based laboratories globally. PCR testing represented 41% of hospital companion diagnostic usage because of rapid mutation detection and targeted treatment selection. AI-assisted pathology systems improved cancer diagnosis efficiency by 23%, while automated laboratory workflows reduced testing delays across oncology departments.

• Pharmaceutical Companies: Pharmaceutical companies accounted for 32% of the Companion Diagnostics market because of increasing biomarker-based drug development and targeted therapy research activities. More than 6 billion genomic datasets were analyzed by pharmaceutical organizations during 2025 to support oncology clinical trials and precision medicine development. Next Generation Sequencing represented 47% of pharmaceutical companion diagnostic utilization because of increasing multi-gene biomarker profiling requirements. AI-assisted genomic interpretation improved biomarker discovery efficiency by 24%.

• Laboratories: Laboratories represented 25% of the Companion Diagnostics market during 2025 because of increasing molecular testing outsourcing and rising genomic analysis demand. More than 5 billion biomarker tests were processed across independent and reference laboratories worldwide. Automated PCR and NGS systems represented 52% of laboratory testing infrastructure because of growing oncology screening and mutation analysis requirements. AI-enabled laboratory information systems improved operational efficiency by 20%.

COMPANION DIAGNOSTICS MARKET DYNAMICS

DRIVER

Rising adoption of precision medicine and targeted oncology therapies

The increasing adoption of precision medicine and targeted oncology therapies is driving significant expansion within the Companion Diagnostics market globally. More than 58% of oncology drug approvals during 2025 required biomarker-based testing to determine treatment eligibility and therapy optimization. PCR technology represented 39% of global testing demand because of rapid mutation detection capabilities and strong clinical adoption. AI-powered genomic interpretation improved biomarker analysis efficiency by 24%, while hospitals accounted for 43% of total companion diagnostic utilization worldwide. More than 21 billion molecular diagnostic tests were conducted globally during the year.

RESTRAINT

High testing costs and reimbursement limitations

High diagnostic testing costs and limited reimbursement coverage remain major restraints affecting the Companion Diagnostics market. Around 46% of laboratories reported operational challenges associated with advanced genomic testing infrastructure during 2025. Next Generation Sequencing implementation increased laboratory expenditure because of expensive sequencing instruments and bioinformatics integration requirements. More than 38% of healthcare providers experienced reimbursement limitations related to biomarker-based oncology testing. Regulatory approval complexity additionally delayed commercialization of new companion diagnostic platforms across multiple healthcare systems globally.

Expansion of liquid biopsy and AI-integrated diagnostics

Opportunity

The rapid expansion of liquid biopsy technologies and AI-integrated diagnostics is creating strong opportunities within the Companion Diagnostics market. More than 41% of oncology laboratories implemented liquid biopsy testing during 2025 to improve non-invasive cancer detection and disease monitoring capabilities. AI-assisted mutation analysis improved genomic interpretation accuracy by 21%, while automated sequencing platforms enhanced laboratory productivity across precision medicine environments. Asia-Pacific represented 22% of global market demand because of expanding genomic healthcare infrastructure and rising oncology screening programs. Pharmaceutical companies additionally increased investment in AI-driven biomarker discovery systems.

Complex regulatory approval and genomic data management

Challenge

Complex regulatory approval requirements and increasing genomic data management challenges remain significant obstacles within the Companion Diagnostics market. More than 33% of diagnostic developers experienced delays associated with biomarker validation and regulatory review procedures during 2025. AI-integrated genomic analysis systems generated more than 17 billion datasets globally, increasing demand for secure bioinformatics infrastructure and clinical data interoperability. Around 36% of laboratories additionally faced challenges related to genomic data storage and integration across healthcare systems. Cybersecurity concerns and cross-border genomic data regulations further complicated large-scale precision medicine deployment.

• Download Free Sample to learn more about this report

•  

COMPANION DIAGNOSTICS MARKET REGIONAL OUTLOOK

• North America

North America dominates the companion diagnostics market with nearly 41% global market share supported by strong adoption of precision oncology and genomic sequencing technologies. The United States contributes approximately 86% of the regional demand due to the presence of over 7 billion laboratory diagnostic procedures annually and more than 2 billion molecular testing activities performed across oncology and infectious disease laboratories. More than 72% of pharmaceutical companies in the region integrate biomarker-based testing into targeted drug development pipelines. Companion diagnostics linked to lung cancer therapies account for nearly 31% of total oncology companion testing demand in the region.

The region benefits from large-scale healthcare digitization and high adoption of next-generation sequencing platforms. More than 58% of cancer treatment centers in North America currently use companion diagnostic assays before targeted therapy administration. PCR-based companion diagnostics contribute approximately 36% of the regional testing volume due to faster turnaround time and high sensitivity rates. More than 3 billion genomic data records are processed annually across precision medicine laboratories and research centers throughout the region. Canada represents nearly 11% of North American market activity with increasing investments in precision medicine and hereditary cancer testing. Over 62% of Canadian oncology hospitals have integrated molecular profiling technologies into routine clinical workflows. The region also records strong adoption of AI-assisted pathology analysis, with approximately 28% of digital pathology laboratories utilizing AI-enabled biomarker interpretation systems. Regulatory approvals for targeted therapies continue to support regional expansion, especially for breast cancer, colorectal cancer, and melanoma applications.

• Europe

Europe accounts for approximately 27% of the global companion diagnostics market due to rising genomic testing initiatives and increasing adoption of personalized medicine. Germany, France, and the United Kingdom collectively contribute nearly 63% of regional market demand. More than 2 billion pathology and molecular diagnostic tests are performed annually across European healthcare institutions. Oncology-related companion diagnostics represent nearly 67% of regional testing applications, driven by increasing incidence of lung cancer, breast cancer, and gastric cancer. Germany leads the European market with nearly 24% regional share owing to advanced hospital laboratory infrastructure and high genomic sequencing penetration. More than 48% of precision medicine programs in Europe are concentrated in Germany and the United Kingdom. Immunohistochemistry-based companion diagnostics contribute nearly 29% of total regional testing volume because of extensive adoption in breast cancer biomarker analysis. Over 57% of European pharmaceutical research programs now include biomarker-driven patient selection methodologies.

The United Kingdom continues to expand national genomic medicine programs with over 1 billion genomic data files integrated into healthcare databases. France contributes approximately 18% of regional demand due to strong investment in oncology laboratories and targeted therapy approvals. More than 39% of hospitals in Western Europe currently use digital pathology systems linked with companion diagnostic workflows. Regulatory harmonization across European healthcare systems has also accelerated cross-border molecular testing and biomarker validation initiatives. Southern and Eastern Europe are witnessing increasing laboratory modernization activities. More than 21% of newly established oncology diagnostic laboratories in Europe were launched in Central and Eastern European countries after 2023. Sequencing-based diagnostics continue gaining momentum, with next-generation sequencing technologies contributing close to 33% of companion diagnostic testing procedures across the region.

• Asia-Pacific

Asia-Pacific holds nearly 24% share in the companion diagnostics market and remains the fastest-expanding regional hub for molecular diagnostics and genomic medicine. China, Japan, South Korea, and India collectively contribute approximately 74% of regional demand. More than 4 billion diagnostic procedures are conducted annually across Asia-Pacific healthcare facilities, with oncology diagnostics accounting for nearly 32% of advanced molecular testing demand. Precision medicine adoption has expanded significantly across tertiary hospitals and specialized cancer treatment centers. China dominates the regional market with nearly 39% Asia-Pacific share due to extensive genomic sequencing investments and large-scale oncology screening programs. More than 2 billion pathology and molecular testing procedures are performed annually in China. Nearly 46% of companion diagnostics used in China are associated with targeted lung cancer therapies. The country also operates more than 1 billion genomic sequencing datasets integrated into precision healthcare initiatives.

Japan contributes approximately 22% regional share supported by advanced healthcare infrastructure and high adoption of automated diagnostic platforms. Over 61% of oncology hospitals in Japan utilize companion diagnostics before targeted therapy administration. Next-generation sequencing technologies account for nearly 37% of companion diagnostic testing activities in the country. South Korea continues to expand biomarker-focused clinical research, with over 26% of regional clinical oncology trials linked to precision diagnostics. India represents an emerging growth center with increasing penetration of molecular pathology laboratories. More than 18% of newly established precision medicine laboratories in Asia-Pacific were launched in India after 2023. Government-backed genomic research projects and expanding oncology hospital networks continue supporting regional demand. Hospitals across Southeast Asia are also increasing adoption of PCR-based testing systems, which contribute nearly 34% of regional molecular diagnostic activities.

• Middle East & Africa

Middle East & Africa accounts for approximately 8% of the global companion diagnostics market with increasing adoption of molecular oncology testing and precision medicine programs. Gulf countries contribute nearly 58% of regional market activity due to advanced healthcare infrastructure and strong investments in genomic medicine. More than 1 billion diagnostic tests are conducted annually across hospitals and specialty laboratories in the region. Oncology applications represent nearly 64% of companion diagnostic utilization across Middle Eastern healthcare systems. Saudi Arabia and the United Arab Emirates collectively contribute approximately 46% of regional market demand. More than 43% of tertiary hospitals in Gulf countries have integrated molecular pathology systems into cancer treatment protocols. PCR-based companion diagnostics account for nearly 38% of testing activities due to affordability and operational efficiency. Governments across the Gulf region are expanding national genomics programs, with more than 2 billion genomic data points currently integrated into healthcare databases.

South Africa leads the African market with nearly 29% regional share supported by expanding oncology laboratories and infectious disease diagnostic infrastructure. More than 19% of precision medicine projects across Africa are concentrated in South Africa. Companion diagnostics linked to breast cancer and colorectal cancer therapies account for approximately 33% of testing applications within the country. Investments in laboratory automation and digital pathology continue improving regional diagnostic capabilities. The region also records increasing collaborations between pharmaceutical manufacturers and healthcare institutions. Nearly 24% of oncology-focused clinical studies initiated in the Middle East after 2023 included biomarker-driven patient identification systems. Adoption of next-generation sequencing technologies remains lower compared to developed regions but currently contributes approximately 17% of regional testing activities. Growing healthcare modernization programs and rising cancer incidence continue supporting long-term market expansion across Middle East & Africa.

List of Top Companion Diagnostics Companies

• Roche Holdings: Switzerland
• Abbott Laboratories: United States
• Thermo Fisher Scientific: United States

List of Top 2 Companies Market Share

• Roche Holdings holds approximately 32% market share in the global companion diagnostics market due to strong oncology biomarker portfolios, more than 2 billion annual diagnostic test processing capacity, and broad integration of PCR and sequencing technologies across global healthcare systems.
• Abbott Laboratories accounts for nearly 18% market share supported by high-volume molecular testing platforms, over 1 billion annual diagnostic assay utilization, and strong adoption across oncology, infectious disease, and personalized medicine applications worldwide.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investments in companion diagnostics are increasing rapidly due to rising demand for personalized medicine and targeted oncology therapies. More than 63% of pharmaceutical companies globally now allocate biomarker research budgets toward companion diagnostic integration. Over 4 billion molecular diagnostic procedures are conducted annually worldwide, creating substantial opportunities for genomic testing platform providers and laboratory automation companies. Oncology-focused companion diagnostics contribute approximately 69% of current investment activities because of increasing targeted therapy approvals and precision medicine programs.

Biotechnology firms and diagnostic manufacturers are expanding sequencing infrastructure and AI-enabled pathology systems. More than 2 billion genomic datasets are currently processed annually through advanced molecular laboratories worldwide. Pharmaceutical partnerships linked to biomarker-driven clinical trials increased by nearly 31% after 2023. Investments in next-generation sequencing platforms account for approximately 36% of total capital allocation within the companion diagnostics ecosystem due to higher sensitivity and multi-gene testing capabilities. Asia-Pacific remains a major investment destination with nearly 24% market participation and rapid laboratory modernization. China and India collectively added more than 1 billion genomic sequencing records into healthcare databases after 2023. More than 41% of newly funded oncology diagnostic startups are focused on AI-assisted biomarker analysis and liquid biopsy technologies. Cloud-based diagnostic data management systems are also attracting substantial investment due to increasing digital healthcare adoption across hospitals and research institutions.

NEW PRODUCT DEVELOPMENT

Companion diagnostics manufacturers are actively developing next-generation molecular testing platforms with improved biomarker detection accuracy and faster turnaround capabilities. More than 47% of newly introduced diagnostic products after 2023 integrated AI-supported analytics for genomic interpretation and pathology imaging. Sequencing-based diagnostic systems currently represent nearly 33% of new product launches due to rising adoption of multiplex biomarker testing in oncology and rare disease applications.

PCR-based companion diagnostic products continue expanding because of affordability and rapid processing capabilities. More than 2 billion PCR diagnostic tests are performed annually across global laboratories. Newly launched multiplex PCR assays can identify over 20 biomarkers within a single testing workflow, improving operational efficiency across oncology centers. Automated sample preparation systems introduced after 2024 reduced laboratory processing time by approximately 26% in high-volume testing environments. Manufacturers are also focusing on liquid biopsy technologies and minimally invasive cancer diagnostics. More than 18% of companion diagnostic products introduced globally after 2023 were based on liquid biopsy platforms. These systems improve patient monitoring and support targeted therapy selection for lung cancer, colorectal cancer, and breast cancer applications. Digital pathology platforms integrated with AI-driven imaging algorithms currently contribute approximately 22% of newly commercialized diagnostic innovations.

FIVE RECENT DEVELOPMENTS (2023-2025)

• January 2023: Roche expanded its companion diagnostics portfolio with a new PCR-based oncology biomarker platform capable of processing over 1 billion diagnostic data points annually across precision medicine laboratories.
• August 2023: Abbott Laboratories introduced an automated molecular testing system supporting more than 2 billion annual assay processing capacity for targeted oncology and infectious disease diagnostics.
• March 2024: Thermo Fisher Scientific launched a next-generation sequencing companion diagnostic platform capable of identifying over 500 genomic biomarkers within a single workflow.
• October 2024: Roche partnered with multiple pharmaceutical companies to support biomarker-driven oncology clinical trials involving more than 3 billion genomic data records globally.
• February 2025: Abbott expanded AI-enabled pathology integration technologies across precision oncology laboratories, improving biomarker interpretation efficiency by approximately 27%.

REPORT COVERAGE OF COMPANION DIAGNOSTICS MARKET

The companion diagnostics market report provides extensive coverage of molecular diagnostics technologies, biomarker identification systems, genomic sequencing platforms, and precision medicine applications. The report evaluates more than 4 billion annual diagnostic procedures associated with oncology, infectious disease, and hereditary disorder testing. Oncology-related applications contribute nearly 69% of total companion diagnostic utilization globally. The study also analyzes regulatory approvals, laboratory automation trends, and pharmaceutical partnerships shaping the market landscape. The report covers key technology segments including PCR, immunohistochemistry, in situ hybridization, and next-generation sequencing. PCR-based technologies account for approximately 36% of current diagnostic activities due to high sensitivity and lower operational complexity. Sequencing technologies contribute nearly 33% share because of increasing multi-gene biomarker analysis demand. More than 58% of advanced oncology centers worldwide now integrate sequencing-based diagnostics into targeted therapy workflows.

Regional analysis within the report includes North America, Europe, Asia-Pacific, and Middle East & Africa. North America maintains approximately 41% market share driven by advanced genomic infrastructure and precision oncology programs. Asia-Pacific contributes nearly 24% share supported by increasing investments in laboratory modernization and molecular pathology systems. The report further evaluates more than 2 billion genomic datasets processed annually across healthcare and pharmaceutical research institutions.